The longevity researcher links out to a longer look at what GLP-1 drugs may offer, where the risks lie, and the microdosing trend.
Recap by typeshit. Post by David Sinclair on X.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
That tops 14.8% on high-dose tirzepatide alone, though 27% dropped out over side effects. CNBC-TV18 says phase 3 is planned by end of 2026.
ASPS member surgeons Drs. Elise Min and Matthew talk about how GLP-1 weight loss can change the breasts.
Loading…